Evidence mapPaperPMID 35318466Full record

ReviewNature reviews. Cardiology2022

Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia.

Jan Borén, Marja-Riitta Taskinen, Elias Björnson, Chris J Packard

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 5 pooled it
44.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 5 syntheses or guidelines pooled it, 283 citations in OpenAlex.

  1. Pooled it
  2. Remnant cholesterol and two decades risk of incident hypertension: a prospective cohort study and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Pooled it
  3. Effects of flavonoids on atherosclerosis in ApoEFrontiers in pharmacology · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. GPR182 is a lipoprotein receptor for dietary fat absorption.The Journal of clinical investigation · 2026
    Article
  19. Review
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Jan BorénDepartment of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. jan.boren@wlab.gu.se.ORCID http://orcid.org/0000-0003-0786-8091
Marja-Riitta TaskinenResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Elias BjörnsonDepartment of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Chris J PackardInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
University of Gothenburg · SEUniversity of Glasgow · GBUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence points to the causal role of triglyceride-rich lipoproteins and their cholesterol-enriched remnants in atherogenesis. Genetic studies in particular have not only revealed a relationship between plasma triglyceride levels and the risk of atherosclerotic cardiovascular disease, but have also identified key proteins responsible for the regulation of triglyceride transport. Kinetic studies in humans using stable isotope tracers have been especially useful in delineating the function of these proteins and revealing the hitherto unappreciated complexity of triglyceride-rich lipoprotein metabolism. Given that triglyceride is an essential energy source for mammals, triglyceride transport is regulated by numerous mechanisms that balance availability with the energy demands of the body. Ongoing investigations are focused on determining the consequences of dysregulation as a result of either dietary imprudence or genetic variation that increases the risk of atherosclerosis and pancreatitis. The identification of molecular control mechanisms involved in triglyceride metabolism has laid the groundwork for a 'precision-medicine' approach to therapy. Novel pharmacological agents under development have specific molecular targets within a regulatory framework, and their deployment heralds a new era in lipid-lowering-mediated prevention of disease. In this Review, we outline what is known about the dysregulation of triglyceride transport in human hypertriglyceridaemia.

Indexed as

AtherosclerosisDyslipidemiasHypertriglyceridemiaAnimalsHumansKineticsLipoproteinsMammalsTriglyceridesLipoproteinsTriglycerides

Identifiers

PMID35318466
OpenAlexW4220891222

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.